SCHEMBL3483906

SCHEMBL3483906

Nc1ccc(Oc2ccc3[nH]ccc3c2)c(Cl)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHR P35869 3/20 0.44
LTA4H P09960 2/20 0.44
NR4A2 P43354 2/20 0.44
F7 P08709 1/20 0.44
F3 P13726 1/20 0.44
PDE7A Q13946 1/20 0.42
THRA P10827 1/20 0.41
THRB P10828 1/20 0.41
HTR2A P28223 1/20 0.40
SLC6A4 P31645 1/20 0.40
KDR P35968 1/20 0.40
RHEB Q15382 3/20 0.39
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
HTT P42858 1/20 0.38
JAK2 O60674 1/20 0.38
SCN9A Q15858 1/20 0.38
MAOA P21397 1/20 0.37
CSNK2A1 P68400 1/20 0.37
PRKCQ Q04759 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3484782 0.89 MEN1 (0.47) AHRPDE7AHTR2ASLC6A4RHEB
SCHEMBL22646562 0.82 THRA (0.53) AHRLTA4HNR4A2F7F3
SCHEMBL8325177 0.78 ROCK1 (0.58) PDE7AHTR2ASLC6A4MAPTHTT
SCHEMBL3484001 0.78 PDE7A (0.59) PDE7ALMNAMAPTHTTGAA
SCHEMBL1913888 0.77 LMNA (0.62) PDE7AHTR2ASLC6A4LMNAMAPT
SCHEMBL4318630 0.76 PDE7A (0.63) PDE7AHTR2ASLC6A4MAPTMAOA
SCHEMBL11460671 0.75 HTR2A (0.63) PDE7AHTR2ASLC6A4
SCHEMBL10962941 0.75 MAPT (0.55) PDE7ATHRBHTR2ASLC6A4LMNA
SCHEMBL29560117 0.74 AHR (0.56) AHRLTA4HNR4A2F7F3
SCHEMBL130519 0.74 AHR (0.56) AHRLTA4HNR4A2F7F3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100004238-A1 FUSED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-07 US disclosed
EP-2103620-A1 FUSED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2009-09-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004238-A1 FUSED HETEROCYCLIC COMPOUND ERBB2, ROS1, FLT3 AHR 259/4885LTA4H 4013/4885NR4A2 506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.